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Infantile spasms (IS) is an age-specific epilepsy which responds to anticonvulsant therapy but has a generally poor 
prognosis for normal psychomotor development. The subgroup of infants with a cryptogenic aetiology or whose 
therapy is initiated promptly is thought to have a more favourable prognosis. We retrospectively reviewed 28 
infants with IS treated between 1990 and 1996 with adrenocorticotropic hormone (ACTH), valproic acid (VPA), or 
both, in order to correlate therapeutic response with long-term outcome. Mean age at onset of treatment was 6.4 
months, with 57% of patients started within 1 month of IS appearance. IS was considered cryptogenic in 39%. The 
majority of infants responded to ACTH or VPA with a reduction in spasms of 75% or more. Total remission of 
seizures occurred in 52%. Death occurred in eight patients; mean duration of follow-up for survivors was 55 
months. All subgroups based on age, aetiology, or treatment had poor outcomes, commonly with residual epilepsy, 
cerebral palsy or mental retardation. Conventional treatment for IS, even when initially successful in reducing 
spasms, is inadequate when viewed from a long-term developmental perspective, suggesting the need for novel 
innovative approaches for treating IS. 
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Infantile spasms (IS) is a poorly understood, 
age-specific epilepsy which has a poor prognosis 
for subsequent normal development’**. Although 
reports indicate a high success rate of seizure 
control with adrenocorticotropic hormone 
(ACTH) therapy”, no studies have demonst- 
rated an equivalent recovery of neurodevelop- 
mental milestones which are lost with the onset of 
IS. Advances in neuroimaging have permitted a 
sharper distinction between symptomatic and 
cryptogenic causes of IS’.‘, but the ability to 
determine which children develop normally follow- 
ing ACTH therapy has not been realized%lo. 
Nevertheless, ACTH is considered standard 
therapy for IS, despite a high incidence of 
side-effects, inability to be used for long periods 
of time, inefficacy for other seizure types, and 
unreliable availability. Intermittently, there has 
been interest in other drugs for control of IS, 
particularly valproic acid (VPA)“-15, which has 
been used primarily when ACTH has failed. We 
report our experience with 28 infants who were 
newly diagnosed with IS and treated between 
1990 and 1995 with either ACTH or VPA as 
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primary therapy and the other drug as alternative 
therapy and their long-term outcomes following 
treatment. 
METHODS 
A diagnosis of IS was made in infants who 
demonstrated clusters of clinical spasms and a 
hypsarrhythmic pattern on electroencephalog- 
raphy (EEG). IS was deemed to be cryptogenic if 
no etiology for seizures could be established 
following magnetic resonance imaging, metabolic 
screening, and genetic studies. In only one infant, 
initially evaluated at another university medical 
centre, was computed tomography used in place 
of magnetic resonance imaging. Developmental 
status was not used to place infants in the 
symptomatic or cryptogenic groups. 
We conducted a retrospective review and 
analysis of medical records approved by the 
hospital review board for human research for 28 
infants referred and diagnosed with IS over a 
B-year period from January, 1990 to December 
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1995, at the Children’s Hospital of the Medical 
University of South Carolina. Treatment of these 
infants was standardized over the period of the 
study. After discussion of risks and benefits of 
therapy with ACTH and with VPA, parents were 
given the option of choosing the primary therapy. 
Infants receiving ACTH were started on ACTH 
gel (20 U) given intramuscularly per day and 
increased by 10 U every 3 days until seizures were 
controlled; a maximum dose of 80 U per day was 
reached and proven ineffective, or side-effects 
developed and prompted tapering of the drug. 
Parents were taught to give ACTH shots and 
infants were monitored at home with home- 
health nurses checking urine glucose, blood 
pressures, and for signs of gastrointestinal bleed- 
ing. For infants receiving VPA, medication was 
initiated after additional screening for hematolo- 
gical or liver abnormalities and organic acid 
disorders, and other anticonvulsant medications 
were being tapered. The starting dose of VPA 
was lOmg/kg/day, increasing over 3 weeks to 
60 mg/kg/day, with trough blood levels rarely 
exceeding 120mg/l. VPA was increased until 
seizures were controlled, blood levels of llO- 
120 mg/l were reached and proven ineffective, or 
side-effects developed and prompted tapering of 
the drug. Regular monitoring included haemo- 
gram with reticulocyte count, liver function 
studies, ammonia, amylase and carnitine. Seizure 
frequency was monitored by the parents and 
(when available) the visiting nurse and recorded 
on seizure calendars. Greater than 75% reduction 
in seizure frequency was used as the indication for 
a positive response to therapy. 
If ACTH or VPA as primary therapy proved to 
be ineffective or poorly tolerated by an infant 
after 2 or 3 weeks, the parents were encouraged 
to use the other drug as alternative therapy, in the 
hope of obtaining the best long-term neurological 
outcome with early control of IS. 
In reviewing outcome following treatment, a 
patient was considered to have mental retarda- 
tion if the language developmental quotient or 
verbal skills on IQ testing were below 70. A 
patient was considered to have cerebral palsy if 
the clinical records documented a non- 
progressive motor deficit since infancy and the 
motor developmental quotient was below 70. 
Neither diagnosis was considered if there was no 
suspicion of abnormality at follow-up after 13 
months of age, or if death occurred at or before 
13 months of age. A patient was considered to 
have later seizures (epilepsy) if unprovoked, 
afebrile epileptic seizures developed and required 
anticonvulsant medication. 
RESULTS 
The 28 infants in the study included 18 boys 
(64%) and 10 girls (36%), with 20 whites (71%) 
and eight blacks (29%). Age of onset of IS ranged 
from 1 to 13 months, with a median of 4.0 months 
and a mean of 4.6 months. Neonatal seizures 
occurred in 46% of the subjects prior to onset of 
IS, and IS presented before age 6 months in 68% 
of patients. Age at beginning of treatment ranged 
from 1 to 15 months, with a mean of 6.4 months. 
Seventeen infants were classified as symptomatic 
(61%) and 11 as cryptogenic (39%). The aetiol- 
ogies for the symptomatic group included perina- 
tal insult (6), genetic (e.g. tuberous sclerosis) (4), 
cerebral dysgenesis (3) cerebral dys- 
genesis with agenesis of the corpus callosum (1) 
metabolic (2), and prenatal insult (1). 
Five patients had been treated with phenobar- 
bital before referral to our centre; three of these 
were started on ACTH and one was started on 
VPA. IS resolved in one child during initial 
phenobarbital treatment, and neither ACTH nor 
VPA was started. Therefore, at the outset of this 
study, primary therapy was ACI’H in 11 patients 
and VPA in 16 patients. Later, six infants 
received ACTH as alternative therapy, and four 
infants received VPA as alternative therapy. 
Therefore, a total of 10 infants received both 
ACTH and VPA at separate times. Among 
infants receiving ACTH, 64% showed an initial, 
positive response to ACTH as primary therapy, 
and 83% showed a response to it as alternative 
therapy; there was therefore a 71% total response 
to ACTH. Among infants receiving VPA, 56% 
showed a positive response to VPA as primary 
therapy, and 50% showed a response as alterna- 
tive therapy, therefore there was a 55% total 
response to VPA. There was no statistically 
significant difference in response between treat- 
ment groups. 
Total remission of IS with treatment occurred 
in 14 infants (52%), six of whom received ACTH 
as primary therapy, three of whom received VPA 
as primary therapy, and five of whom received 
both ACTH and VPA. Long-term outcome did 
not differ significantly between the 11 patients 
treated initially with ACTH and the 16 patients 
treated initially with VPA [Table l(a) and (b)]. 
Nor did outcome differ significantly between the 
17 patients with symptomatic IS and the 11 
patients with cryptogenic IS (Table 2). Com- 
parison of long-term outcomes in the groups who 
received ACTH only, VPA only, or ACTH and 
VPA were strikingly similar for other seizure 
occurrence, cerebral palsy, mental retardation, 
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Table l(a): Outcome of IS by initial treatment 
ACTH initially 
(n = 11)’ 
VPA initially 
(n = 16)a 
Later seizures 
Cerebral palsy (CP) 
Mental retardation (MR) 
Minor neurological signs 
Death 
8 (80%) 12 (86%) 
10 (100%) 11 (79%) 
10 (100%) 12 (86%) 
0 1 (7%) 
2” (18%) SC (31%) 
“The entire number of patients (n) is used to calculate percentage of patients who died. The number of patients who survived past 
13 months-of-age is used to calculate percentage of patients with seizures, CP, MR, or minor neurological signs. 
b One died before 13 months-of-age. 
‘Two died before 13 months-of-age. 
Table i(b): Outcome of IS by treatment category 
ACTH only 
(n = 7) 
VPA only 
(n = lo)8 
ACTH and VPA 
(n = 10) 
Later seizures 4 (67%) 9 (100%) 7 (78%) 
Cerebral palsy (CP) 6 (100%) 7 (78%) 7 (78%) 
Mental retardation (MR) 6 (100%) 8 (89%) 8 (89%) 
Minor neurological signs 0 1 (11%) 1 (11%) 
Death lb (14%) 3b (30%) 3b (30%) 
a The entire number of patients (n) is used to calculate percentage of patients who died. The number of patients who survived past 
13 months-of-age is used to calculate percentage of patients with seizures, CP, MR, or minor neurological signs. 
‘One died before 13 months-of-age. 
minor neurological abnormalities, and death. The 
most convincing finding for all groups was that 
long-term prognosis was poor: epilepsy 
developed later in 21 of 25 (84%), various types 
of cerebral palsy in 21 of 25 (84%), and mild, 
moderate, or severe mental retardation in 23 of 
25 (92%). Death occurred in eight patients, aged 
from 4 to 38 months; the mean age at death was 
20 months. Follow-up for the 20 survivors ranged 
from 23 to 88 months after initial diagnosis of IS: 
the mean duration of follow-up for survivors was 
55 months. Of the eight deaths, only one was 
related to treatment (sepsis while on ACTH); the 
others died from their underlying disease. Only 
two infants (7%) had mild non-handicapping 
Table 2: Outcome of treatment bv IS cateaorV 
Symptomatic 
(n = 17) 
Cryptogenic 
(n = 11)” 
Later seizures 13 (87%) 8 (80%) 
Cerebral palsy (CP) 13 (87%) 8 (80%) 
Mental retardation (MR) 13 (87%) 10 (100%) 
Minor neurological signs 2 (13%) 0 
Death 6’ 135%) 2b (18%) 
conditions: well-controlled seizures in one, and 
monoparesis in the other. None of the children 
was neurologically normal at the conclusion of 
the follow-up period. 
We were unable to validate earlier findings that 
rapid institution of treatment correlates with 
improved outcome (Table 3). This study found 
that treatment for IS was begun within 30 days of 
seizure onset in 57% of patients and after 30 days 
in 43% of patients. The symptomatic and 
cryptogenic IS patients were evenly divided 
between both early treatment and late treatment 
groups. The incidence of death and of other 
Table 3: Outcome of treatment by promptness in initiating 
treatment after onset of IS 
Within 30 days 
(n = 16)” 
Later seizures 11 (79%) 
Cerebral palsy (CP) 13 (93%) 
Mental retardation (MR) 13 (93%) 
Minor neurological signs 2 (14%) 
Death 5’ (31%) 
After 30 days 
(n = 12)’ 
10 (91%) 
8 (73%) 
10 (91%) 
0 
3b (25%) 
a The entire number of patients (n) is used to calculate 
percentage of patients who died. The number of patients who 
survived past 13 months-of-age is used to calculate percentage 
of patients with seizures, CP, MR, or minor neurological signs. 
‘One died before 13 months-of-age. 
‘Two died before 13 months-of-age. 
“The entire number of patients (n) is used to calculate 
percentage of patients who died. The number of patients who 
survived past 13 months-of-age is used to calculate percentage 
of patients with seizures, CP, MR, or minor neurological signs. 
b One died before 13 months-of-age. 
‘Two died before 13 months-of-age. 
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adverse outcomes was the same in 
treatment and late treatment groups. 
both early 
DISCUSSION 
seizures does not necessarily produce improve- 
ment of brain dysfunction. These current findings, 
which replicate those of some previous studies, 
should help ‘clear the deck’ for new treatment 
approaches. Vigabatrin may offer a novel ap- 
proach for treating IS26, although there is yet no 
information about long-term developmental out- 
come of children whose spasms have been 
suppressed by this drug. 
The findings of this retrospective study add to the 
abundance of published data that challenge 
conventional thinking about IS. Firstly, the 
prospects for a favourable outcome are not as 
good as paediatricians often lead patients to 
believe. This study, like others, failed to replicate 
the guardedly optimistic results of Bellman16, who 
reported that, of 267 patients with infantile 
spasms, 30% later had normal intelligence and 
only 26% went on to develop epilepsy. We found 
cognitive impairment in 92% of our patient 
population and observed that 84% developed 
later epilepsy. There appears to be little basis for 
the current teaching that one-third of infants with 
IS may be normal following treatment. Criteria 
predictive of a favourable outcome” include age 
of onset greater than 6 months. Our experience, 
which is typical of most small referral centres, 
showed that 68% of patients with IS presented at 
less than 6 months of age. Furthermore, our 
experience fails to confirm that better results can 
be achieved with prompt treatment, as proposed 
by others’s*19. 
Secondly, ACTH appears to be an effective, 
but not a superior drug, whether it is given in a 
low dose2o*2’ or a high dose2*4*s. While some 
investigators have observed that outcome with 
ACTH is no different from without any 
treatment8*22Yu, others continue to find only 
‘relatively normal development’ in a minority of 
patients24*E. Our findings suggest that VPA is as 
effective as ACTH in promoting remission of IS 
and as ineffective as ACTH in facilitating later 
normal cognitive development. 
Thirdly, the findings demonstrate that conven- 
tional strategies for treating IS are reasonably 
successful in treating seizures but less adequate if 
long-term outcomes are used as a measure of 
success. When viewed from this perspective of 
global function rather than seizure control, it 
seems that none of our current drugs for treating 
IS produces a satisfactory outcome beyond 
seizure control. Whether the standard therapy 
with ACTH or alternative therapy with VPA is 
used, the likelihood of normal development 
remains very small. This is most probably an 
indication that IS and cognitive impairment are 
both consequences of underlying brain dysfunc- 
tion, and that satisfactory treatment of the 
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